藥師幫(09885.HK):超額配發142.66萬股額外籌約2720萬港元 穩定價格行動及穩定價格期間結束
格隆匯7月20日丨藥師幫(09885.HK)宣佈,於2023年7月20日,獨家整體協調人(代表國際承銷商)已就合共142.66萬股股份("超額配發股份",相當於根據全球發售於任何超額配股權獲行使前初步可供認購的發售股份總數約9.02%),部分行使招股章程及日期為2023年6月27日的發售價格及配發結果公吿所述的超額配股權,以便(其中包括)向MIYT Holdings Limited歸還穩定價格操作人根據借股協議借入的237.12萬股股份中的部分股份,該等股份乃用於補足國際發售的超額分配。
公司將按每股發售股份20.0港元(即全球發售項下的每股發售股份發售價)發行及配發超額配發股份。聯交所上市委員會已批准超額配發股份上市及買賣。
超額配發股份將於2023年7月25日(星期二)上午九時正開始在聯交所主板上市及買賣。
經扣除公司就部分行使超額配股權所應付的承銷費用、佣金及估計開支後,公司將就發行超額配發股份額外收取所得款項淨額約2720萬港元。
此外,與全球發售有關的穩定價格期及穩定價格行動已於2023年7月20日(即截止遞交香港公開發售申請日期後第30日)結束。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.